Didier Blondel - ABIVAX Société CFO, Board Secretary
| AAVXF Stock | USD 11.05 0.00 0.00% |
CFO
Mr. Didier Bruno Blondel was Chief Financial Officer and Board Secretaryt of Abivax SA since January 2, 2017 since 2017.
| Tenure | 7 years |
| Phone | 33 1 53 83 08 41 |
| Web | https://www.abivax.com |
ABIVAX Société Management Efficiency
The company has return on total asset (ROA) of (0.4368) % which means that it has lost $0.4368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.8647) %, meaning that it generated substantial loss on money invested by shareholders. ABIVAX Société's management efficiency ratios could be used to measure how well ABIVAX Société manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CFO Age | ||
| Michelle Robertson | Geron | 57 | |
| Olivia Bloom | Geron | 55 | |
Management Performance
| Return On Equity | -12.86 | |||
| Return On Asset | -0.44 |
ABIVAX Socit Anonyme Leadership Team
Elected by the shareholders, the ABIVAX Société's board of directors comprises two types of representatives: ABIVAX Société inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIVAX. The board's role is to monitor ABIVAX Société's management team and ensure that shareholders' interests are well served. ABIVAX Société's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIVAX Société's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Didier Blondel, CFO, Board Secretary | ||
| Alain Chevallier, Advisor | ||
| Philippe MD, Founder Director | ||
| Regina Jehle, VP Communications | ||
| Prof Ehrlich, Chief Officer | ||
| Paul Gineste, VP Operations | ||
| Anne Pascard, HR Mang | ||
| Raquel Lizarraga, Investor Mang | ||
| Pierre MBA, Chief Devel | ||
| Alexandra Pearce, Vice President and Head of Regulatory Affairs |
ABIVAX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ABIVAX Société a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.86 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | 4.66 % | |||
| Current Valuation | 165.28 M | |||
| Shares Outstanding | 22.3 M | |||
| Shares Owned By Insiders | 4.67 % | |||
| Shares Owned By Institutions | 57.27 % | |||
| Price To Earning | (7.88) X | |||
| Price To Book | 27.57 X | |||
| Price To Sales | 20.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in ABIVAX Pink Sheet
ABIVAX Société financial ratios help investors to determine whether ABIVAX Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABIVAX with respect to the benefits of owning ABIVAX Société security.